View Clinical Trial (Medical Research Study)

Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides - NCT00187733-94143(Clinical Trial 129416)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  San Francisco
State:  
CA
Zip Code: 94143
Conditions: Healthy
Purpose: The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. Previously, the investigators have recruited a cohort of healthy volunteers (Studies of Pharmacogenetics in Ethnically-Diverse Populations, or SOPHIE) and have resequenced the coding region of a number of membrane transporter genes to identify genetic polymorphisms in these genes. Subjects in this cohort have agreed to be called back for recruitment in further studies based on their own genetic sequence, allowing the investigators the possibility to prospectively study the influence of genetic polymorphisms on particular phenotypes (i.e., genotype-to-phenotype studies). The investigators plan to take a genotype-to-phenotype approach to study the influence of specific polymorphisms in the novel organic cation transporter 2 (OCTN2) gene on carnitine and lipid metabolism in healthy subjects.
Study summary:
Criteria: Inclusion Criteria: - Previous participation in the "SOPHIE" study - Between the ages of 18 and 40 years old - Have a pre-selected genotype for OCTN1 and OCTN2 - Have been selected as healthy by medical history questionnaire and screening blood work (complete blood count [CBC], comprehensive metabolic panel). Exclusion Criteria: - Pregnant at the time of the study - Have a new history indicating they are no longer healthy - Taking a medication that could confound study results - Individuals with anemia (hemoglobin < 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL). - Do not consent to participate in the study.
Study is available at: San Francisco General Hospital
San Francisco, CA 94143
United States

Primary Contact:
Tom Urban, PharmD
Email: urbant@pharmacy.ucsf.edu
Phone: 415-476-6756

Secondary Contact:
Tom Urban, PharmD
Email: urbant@pharmacy.ucsf.edu
Phone: 415-476-6756
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.